Mainz Biomed (QUCY) Q1 2026 earnings summary

Executive summary

• Strategic shift to focus on pancreatic cancer screening and post-quantum cybersecurity, exiting colorectal cancer business with asset sales completed in March and April 2026.

• Leadership changes included appointing a new non-executive Chairman and CEO to align with the new business direction.

• Company rebranded to Quantum Cyber N.V. and changed its NASDAQ ticker to QUCY.

Financial highlights

• Net loss from continuing operations was $2.5 million for Q1 2026, down 10% year-over-year.

• Net loss from discontinued operations was $2.6 million, up 16% year-over-year.

• Total net loss for Q1 2026 was $5.1 million, a 2% increase from Q1 2025.

• Cash and cash equivalents at March 31, 2026 were $4.75 million, up from $0.89 million at year-end 2025.

• Operating cash outflows improved to $2.7 million from $3.9 million year-over-year.

Outlook and guidance

• Focus on commercializing blood-based pancreatic cancer screening and expanding into post-quantum cybersecurity.

• Management expects current cash and planned financing to cover expenditures for at least one year, but substantial doubt remains about long-term viability.